Get the Stockscreener App
8.22
1.48%
0.12
After Hours:
8.21
-0.010
-0.12%
Regulus Therapeutics Inc stock is traded at $8.22, with a volume of 2.78M.
It is up +1.48% in the last 24 hours and up +4.98% over the past month.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
See More
Previous Close:
$8.10
Open:
$8.12
24h Volume:
2.78M
Relative Volume:
1.39
Market Cap:
$549.03M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
-5.2025
EPS:
-1.58
Net Cash Flow:
$-27.38M
1W Performance:
+3.66%
1M Performance:
+4.98%
6M Performance:
+413.75%
1Y Performance:
+268.61%
1-Day Range:
$8.07
$8.28
1-Week Range:
$7.91
$8.28
52-Week Range:
$0.8301
$8.28
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Name
Regulus Therapeutics Inc
Sector
Industry
Phone
858-202-6300
Address
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Compare RGLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
8.22 | 549.03M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Mar-18-24 | Initiated | Leerink Partners | Outperform |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Jan-05-18 | Initiated | Leerink Partners | Outperform |
| Jun-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Mar-06-17 | Reiterated | Wedbush | Outperform |
| Jan-30-17 | Downgrade | Needham | Buy → Hold |
| Jan-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Dec-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Nov-02-16 | Reiterated | Needham | Buy |
| Jul-25-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | FBR Capital | Outperform |
| Jun-28-16 | Reiterated | Needham | Buy |
| Jun-07-16 | Reiterated | Chardan Capital Markets | Buy |
| Apr-13-16 | Initiated | Chardan Capital Markets | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Apr-21-15 | Resumed | FBR Capital | Outperform |
| Nov-24-14 | Initiated | Deutsche Bank | Buy |
| Aug-07-14 | Reiterated | FBR Capital | Outperform |
| Aug-14-13 | Reiterated | Needham | Buy |
View All
Regulus Therapeutics Inc Stock (RGLS) Latest News
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus
Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News
Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times
Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Regulus (RGLS) Sees Increased Put Trading Activity | RGLS Stock News - GuruFocus
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - San Diego Union-Tribune
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus
Regulus (RGLS) Downgraded After Acquisition Agreement with Novar - GuruFocus
Regulus Therapeutics Inc (RGLS): Shares Soar 137% on Acquisition News - Wealth Daily
Regulus Therapeutics Inc Stock (RGLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):